Merck (NYSE: MRK) reported Q2 EPS of $0.86, $0.05 better than the analyst estimate of $0.81. Revenue for the quarter came in at $9.8 billion versus the consensus estimate of $9.8 billion.

Merck sees FY2015 EPS of $3.45-$3.55, versus the consensus of $3.45.

“We’re investing resources to grow our strongest brands and to support the most promising assets in our pipeline, while at the same time lowering our cost base and delivering operating leverage.”

“We’ve made significant progress this quarter in two of our most important assets, the KEYTRUDA and hepatitis C programs, and will be fully prepared to take advantage of these potentially breakthrough opportunities.”

“We’re witnessing the introduction of breakthrough therapies for some of the most difficult-to-treat diseases. Merck’s late-stage pipeline and ongoing launches reflect scientific and therapeutic progress with the potential to provide significant value to patients and society.”

For earnings history and earnings-related data on Merck (MRK) click here.